Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
